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Treatment of cancer with chemotherapy and radiation therapy has severe side effects that damage healthy proliferating cells such as hematopoietic precursors, hair follicle, cells and the epithelial lining of the intestine. These side effects often limit the doses of chemotherapy administered, allowing tumor cells to gain growth advantage by escaping treatment and developing drug resistance. Since cancer therapy targets proliferating cells and tissues, all cells that proliferate, whether normal or tumor are affected by the treatment. If however the normal dividing cells in the body were to stop proliferating reversibly, the toxic effects of chemotherapy would potentially be diminished. Here, we introduce a novel therapeutic strategy to selectively target cancer cells, while leaving nomial proliferating cells intact by taking advantage of differences in cell cycle regulation between normal and tumor cells.The approach taken for this "protection" strategy involves two steps: First, the normal proliferating cells are blocked in the G0/G1 phase of the cell cycle by pre-treatment with cytostatic, non-lethal agents. Tumor cells will not respond to these agents, because they have lost the G0/G1 checkpoint; they will continue to proliferate. Next, both normal and tumor cells are treated with conventional chemotherapeutic agents which will specifically kill proliferating tumor cells. Normal cells are protected because of the G0/G1 mediated reversible arrest achieved in the first step. Our goal for this one year concept award is to examine the feasibility of our hypothesis against drug resistant tumor cells in culture and to initiate a pilot study in vivo to examine the pre-clinical applicability of our hypothesis in mice. 
SUBJECT TERMS

Introduction:
The overall purpose of this 1 year study was to initiate an in vivo study in mice examining the feasibility of a treatment strategy where normal cells are protected from the toxic effects of chemotherapeutic agents, by reversibly arresting them in the Gl phase of the cell cycle.
Body:
Treatment of cancer with chemotherapy and radiation therapy has severe side effects that damage healthy proliferating cells such as hematopoietic precursors, hair follicle, cells and the epithelial lining of the intestine. These side effects often limit the doses of chemotherapy 
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To explore the feasibility of cellular protection through reversible cell cycle arrest, we target the pRb (retinoblastoma) pathway, which governs the transition from GO/Gl to S, or the restriction point (8). pRb is a major tumor suppressor that is frequently inactivated in human cancer. Furthermore, alterations in pRb are linked to poor prognosis, tumor progression, and decreased sensitivity to chemotherapeutic agents (9-13). As an important tumor suppressor, pRb is involved in controlling the progression through GO/Gl. The hypo-phosphorylated pRb serves Specificallv. our objective was to examine the efficacv of the protection strateev in mice.
Results/Key Research Accomplishments:
During the past year we were successful in initiating our prospective analysis and providing initial results of the feasibility of our protection strategy. We used UCN-01 as the agent to arrest the normal rapidly proUferating epithelial lining of the intestine in the Gl phase of the cell cycle.
UCN-01 Inhibition of normal hyperproliferative cells in mice We performed initial in vivo
dose response studies with UCN-01 in nude mice using the normal rapidly dividing intestinal epithelial cells as the normal tissue end point (Fig 1) . We performed four sets of experiments (6 mice 
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For these initial studies we labeled mice with 60mg/kg BrdUrd in PBS as an i.p. injection. At 20 minutes and 6 hours post BrdUrd injection, mice were sacrificed and the jejunum fixed overnight. The jejunal mucusal cells were collected, nuclei isolated, and labeled with FITCconjugated dual antibody for BrdUrd and DNA content (propidum iodide) for 24 hours and then subjected to flow cytometry (Fig 1) . Using the analysis represented in Additionally the fraction fld(t) of BrdUrd-labeled divided cells at 6 hours was also reduced by a factor of 2 to 0.63% (Fig lA) . These During the one-year study, we have accomplished the goal set forth by our proposal. We have examined the feasibility of using a cytostatic agent in vivo to arrest the normal rapidly proUferating cells of the intestine in Gl. This complex in vivo assay is now functional in our laboratory and we are now in a position to examine the ability of other, more clinically relevant, cytostatic agent in vivo.
